Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Oxford Radcliffe Hospital |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00644319 |
RATIONALE: Morphine and ibuprofen help lessen pain caused by pleurodesis. It is not yet known whether one drug is more effective than the other in lessening pleurodesis-related pain or whether the size of the chest drain tube affects pain.
PURPOSE: This randomized clinical trial is studying ibuprofen to see how well it works compared with morphine in treating pain in patients undergoing pleurodesis for malignant pleural effusion.
Condition | Intervention | Phase |
---|---|---|
Metastatic Cancer |
Drug: ibuprofen Drug: morphine sulfate Procedure: management of therapy complications Procedure: pleurodesis |
Phase II |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized |
Official Title: | A 2 x 2 Factorial Trial to Assess Whether Non-Steroidal Anti-Inflammatory Analgesics and Small Bore Chest Tubes Are Less Painful Than Opiate Analgesics and a Large Bore Chest Tubes in Pleurodesis for Malignant Pleural Effusion [TIME1] |
Estimated Enrollment: | 320 |
Study Start Date: | March 2007 |
Estimated Primary Completion Date: | September 2009 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
OUTLINE: This is a multicenter study. Patients are stratified according to histological tissue type (mesothelioma vs non-mesothelioma) and thoracoscopic procedure. Patients are randomized to 1 of 4 treatment arms.
All patients will receive regular background analgesia comprising paracetamol 4 times daily on days 0-3. Patients not adequately treated with these regimens may also receive rescue analgesia comprising morphine sulfate IV on days 0-3.
After completion of study treatment, patients are followed at 1, 3, and 6 months, and periodically thereafter.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Diagnosis of malignant pleural effusion requiring pleurodesis confirmed by 1 of the following:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
No other concurrent analgesics
No concurrent enrollment on another clinical study
United Kingdom, England | |
Oxford Radcliffe Hospital | Recruiting |
Oxford, England, United Kingdom, 0X3 9DU | |
Contact: Contact Person 44-1865-225-205 robert.davies@ndm.ox.ac.uk |
Principal Investigator: | Robert Davies, MD | Oxford Radcliffe Hospital |
Study ID Numbers: | CDR0000590072, RADCLIFFE-TIME1, ISRCTN33288337, EUDRACT 2006-005226-31, EU-20829, UKCRN 4035 |
Study First Received: | March 25, 2008 |
Last Updated: | July 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00644319 History of Changes |
Health Authority: | Unspecified |
malignant pleural effusion |
Thoracic Neoplasms Anti-Inflammatory Agents Morphine Ibuprofen Pleural Diseases Cyclooxygenase Inhibitors Central Nervous System Depressants Pleural Effusion, Malignant Narcotics Pain |
Pleural Effusion Respiratory Tract Diseases Analgesics, Non-Narcotic Neoplasm Metastasis Anti-Inflammatory Agents, Non-Steroidal Peripheral Nervous System Agents Analgesics Antirheumatic Agents Analgesics, Opioid Pleural Neoplasms |
Thoracic Neoplasms Anti-Inflammatory Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs Pleural Effusion, Malignant Neoplastic Processes Neoplasms by Site Pathologic Processes Respiratory Tract Diseases Sensory System Agents Therapeutic Uses Neoplasm Metastasis Anti-Inflammatory Agents, Non-Steroidal Analgesics Analgesics, Opioid |
Respiratory Tract Neoplasms Morphine Ibuprofen Pleural Diseases Cyclooxygenase Inhibitors Central Nervous System Depressants Narcotics Enzyme Inhibitors Pharmacologic Actions Pleural Effusion Neoplasms Analgesics, Non-Narcotic Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |